tirzepatide pittsburgh Cardiometabolic Gains Backslide After Halting Obesity Meds Tirzepatide in Pennsylvania | Zepbound®

States including California, New York, and Massachusetts have expanded coverage to include weight loss as an indication for GLP-1 agonists, while others restrict reimbursement to type 2 diabetes and cardiovascular risk reduction only

If you have already tried a GLP-1 only agent (liraglutide, semaglutide) and hit a plateau, retatrutide's triple agonist mechanism addresses receptor pathways those drugs do not touch meaningful escalation rather than a lateral move

Day 2021, 1.7 nmol/kg/day

Around 1 in 4 participants reported gastrointestinal side effects like stomach pain, nausea, and vomiting, although only one person chose to stop taking GLP-1 drugs during the study